Beate Jahn1, Marjan Arvandi1, Ursula Rochau1,2, Heidi Fiegl3, Georg Goebel4, Christian Marth3, Uwe Siebert1,2,5,6. 1. Institute of Public Health, Medical Decision Making & Health Technology Assessment, Department of Public Health, Health Services Research & Health Technology Assessment, UMIT - University for Health Sciences, Medical Informatics & Technology, Hall in Tirol, Austria. 2. ONCOTYROL, Division of Health Technology Assessment & Bioinformatics, ONCOTYROL - Center for Personalized Cancer Medicine, Innsbruck, Austria. 3. Department of Obstetrics & Gynaecology, Medical University of Innsbruck, Innsbruck, Austria. 4. Department of Medical Statistics, Informatics & Health Economics, Medical University of Innsbruck, Innsbruck, Austria. 5. Center for Health Decision Science, Department of Health Policy & Management, Harvard T.H. Chan School of Public Health, Boston, MA, USA. 6. Institute for Technology Assessment & Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Abstract
AIM: To develop a prognostic score for primary breast cancer patients integrating conventional predictors and the novel biomarker CHAC1 to aid adjuvant chemotherapy decisions. PATIENTS & METHODS: A prognostic score for overall survival was developed using: conventional predictors from a dataset of 1777 patients and the weight of CHAC1 mRNA expression from an independent dataset of 106 patients using multivariate Cox regression. RESULTS: The new score includes: CHAC1 mRNA expression, age, tumor size, HER2 neu status, lymph node status and degree of malignancy. Using a cut-off value of 11 score points, 10-year survival was 82% in low-risk (n = 34) and 43% in high-risk patients (n = 72). The addition of CHAC1 resulted in 16% reclassification. CONCLUSION: Including CHAC1 in prognostic prediction may aid (and change) personalized treatment selection.
AIM: To develop a prognostic score for primary breast cancerpatients integrating conventional predictors and the novel biomarker CHAC1 to aid adjuvant chemotherapy decisions. PATIENTS & METHODS: A prognostic score for overall survival was developed using: conventional predictors from a dataset of 1777 patients and the weight of CHAC1 mRNA expression from an independent dataset of 106 patients using multivariate Cox regression. RESULTS: The new score includes: CHAC1 mRNA expression, age, tumor size, HER2 neu status, lymph node status and degree of malignancy. Using a cut-off value of 11 score points, 10-year survival was 82% in low-risk (n = 34) and 43% in high-risk patients (n = 72). The addition of CHAC1 resulted in 16% reclassification. CONCLUSION: Including CHAC1 in prognostic prediction may aid (and change) personalized treatment selection.